Abstract 92P
Background
Nutrition and immune status are two important factors that affect the occurrence and prognosis of tumors. Evaluating the nutritional and immune status of patients before treatment plays an important role in guiding the development of treatment plans and predicting treatment tolerance. In view of this, this study investigated the nutritional and immune status (BMI, PNI, and lymphocyte subset (NKTB) typing and absolute count) of nasopharyngeal carcinoma patients before treatment, and compared them with the nutritional and immune status of healthy individuals undergoing physical examinations, hoping to provide reference for the assessment of nutritional and immune status of nasopharyngeal carcinoma patients before treatment.
Methods
The study investigated the pretreatment nutritional and immune status (BMI, PNI, and percentage and absolute count of lymphocyte subpopulation) of 201 Newly diagnosed NPC cases and 332 age-sex-matched healthy controls.
Results
PNI was lower in patients with NPC than in healthy controls in both sexes and at different age groups (P < 0.001). Healthy controls had higher BMI than those with NPC (P < 0.005), but there was no difference across the age subgroups. In the NPC group, the absolute numbers of LYM, ALB, and TBNK (CD3+, CD3+CD4+, CD3+ CD8 +, CD16+CD56+, and CD19+) cell subsets were lower than those in the healthy control group (P < 0.001). A comparison of lymphocyte subpopulations in nasopharyngeal carcinomas at different stages revealed that CD3+CD8+(%) in N3 patients was higher than in N0-2. Patients who acquired metastases had higher CD19+ (%). The multifactorial combination index for the differential diagnosis of NPC, which included PNI, EBV, and immunological status, had a sensitivity of 81.59% and specificity of 96.08%.
Conclusions
The nutritional and immune statuses of NPC patients were reduced prior to treatment, and the evaluation of nutritional and immune statuses prior to treatment of patients with NPC at the time of diagnosis is of guiding significance for subsequent anti-tumor treatment, which is worth promoting and applying in the clinic.
Legal entity responsible for the study
The authors.
Funding
Sichuan Science and Technology Program (2023NSFSC1446).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
Resources:
Abstract
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
Resources:
Abstract
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
Resources:
Abstract
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
Resources:
Abstract
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
Resources:
Abstract
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
Resources:
Abstract
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
Resources:
Abstract
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session
Resources:
Abstract
133P - The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced non-small cell lung cancer: A single-arm, open-label, multicenter phase II clinical trial
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract
134P - Intracranial (IC) progression-free survival (PFS) with ivonescimab (Ivo) compared to placebo in the HARMONi-A trial of patients (Pts) with previously treated EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC)
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract